AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca’s ongoing Phase II umbrella study, officially titled An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients With Non-Small Cell Lung Cancer, Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON), aims to evaluate new anti-cancer agents for patients with metastatic non-small cell lung cancer (NSCLC) who have not responded to previous treatments. The study is significant as it addresses the urgent need for novel therapies in this patient group.
The study tests various experimental drug combinations, including Durvalumab paired with other agents like Olaparib, AZD9150, and Vistusertib, among others. These combinations are designed to assess their efficacy, safety, and tolerability in treating NSCLC.
This interventional study is non-randomized with a parallel assignment model, and it is open-label, meaning both researchers and participants know which treatments are being administered. The primary purpose is to find effective treatments for NSCLC patients who have exhausted other options.
The study began on December 18, 2017, with its primary completion and estimated completion dates yet to be disclosed. The latest update was submitted on July 23, 2025, indicating ongoing progress.
This clinical update could potentially boost AstraZeneca’s stock performance and investor confidence, given the high demand for effective cancer treatments. The study’s outcomes may also influence the competitive landscape in the oncology sector.
The study is currently active but not recruiting, with further details available on the ClinicalTrials portal.